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Abstract. Objective: FXYD-3, also known as Mat-8, is a member of the FXYD protein family. It was reported that this
protein can associate with and modify the transport properties of Na, K-ATPase, and may play an important role in a variety
of physiological and pathological states. This protein is up-regulated in certain types of cancers (such as breast, prostate and
pancreatic cancer), but down-regulated in other types of cancers (such as colon and kidney cancer). No study has been performed
in gastric cancer; therefore, the aim of this project was to investigate FXYD-3 expression and its clinicopathological significance
in gastric adenocarcinoma.
Patients and methods: FXYD-3 protein was examined by immunohistochemistry in normal gastric mucous (n = 29) and gastric
adenocarcinoma (n = 51), obtained from surgical resection of gastric cancer patients.
Results: FXYD-3 protein was present in the cytoplasm of normal gastric epithelial cells or gastric cancer cells. The rate of
FXYD-3 strong expression was significantly higher in cancer (51% of 51) than in normal mucosa (10% of 29, X2=13.210, p <
0.0001). FXYD-3 expressed strongly in ulcerative/infiltrating types of cancers compared to polypoid/fungating ones (X2 =
5.765, p = 0.016). However, FXYD-3 expression was not correlated with patient’s gender, age, tumor size, lymph node status
and histological grade (p > 0.05).
Conclosion: Up-regulated expression of FXYD-3 protein may be involved in tumourgenesis and invasion of gastric adenocarci-
noma.
Keywords: FXYD-3, gastric cancer, immunohistochemistry
∗Corresponding author: Prof. Xiao-Feng Sun, M.D. Ph.D., Depart-
ment of Oncology, Institute of Clinical and Experimental Medicine,
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1. Introduction
The FXYD proteins constitute a family of conserved
auxiliary subunits of the Na, K-ATPase, and have been
the study focus in biomedicine field recently due to
their ability to finely regulate the activity of the en-
zyme complex in various physiological and pathologix-
cal settings [1].
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The FXYD protein family contains seven members
that are small, single-span membrane proteins charac-
terized by a signature sequence containing an FXYD
motif and three other conserved amino acid residues [1,
2]. Recent evidences suggest that all members includ-
ing FXYD-1 (phospholemman) [3], FXYD-2 (gamma
subunit of Na, K-ATPase) [4], FXYD-3 (mammary tu-
mor marker 8, also called as Mat-8) [5], FXYD-4 (cor-
ticosteroid hormone-inducedfactor, CHIF) [6], FXYD-
5 (protein related to ion channel, Ric) [7], FXYD-6
(phosphohippolin) [8]and FXYD-7 [9] associate with
Na, K-ATPase in a tissue-specific way and modulate its
transport properties.
FXYD-3 was identified as a transmembrane protein,
which is expressed in a subset of murine breast tu-
mors [5,10]. Although it is a member of the FXYD
family, it differs from the most of the other members.
It has a signal peptide that is uncleaved and completely
different by being the only one with two transmembrane
domains. The other members have only one transmem-
brane dormain [1]. It is reported that FXYD-3 is ex-
pressed not only in normal tissues but also in tumors.
In normal tissues it is mainly expressed in the uterus,
stomach, colon and skin. And in tumor tissue it has
been found in breast, colon and prostate tumors. Inter-
estingly, in some types of cancers such as prostate [11]
and pancreatic cancer [12], FXYD-3 is up-regulated
and in others such as colon and kidney cancer [12] it is
down-regulated. Moreover, it was shown that FXYD-3
was expressed in breast tumor initiated by the onco-
genes c-neu or v-Ha-ras, but not by c-myc [10]. And
Grzmil et al. [11] showed that small interfering RNA
(SiRNA)-mediated inhibition of FXYD-3 expression
promotes a decreased proliferation in prostate cancer
cell line. However, to our knowledge, no study has
been performed in gastric cancer yet, therefore, in the
present study, we examined FXYD-3 protein expres-
sion in normal gastric samples and gastric adenocar-
cinomas, and further explored its clinicopathological
significance in the patients.
2. Materials and methods
2.1. Materials
For immunohistochemistry formalin fixed paraffin-
embedded tissue samples were obtained from 51 gas-
tric adenocarcinoma patients who underwent surgical
resection at the First Hospital of Hebei Medical Uni-
versity (Shijiazhuang, Hebei Province, China), during
2001–2006. The study included 29 distant normal mu-
cosa specimens (they all were matched with the pri-
mary tumors) taken from the margin of distant resec-
tion. Among the primary tumors, 34 cases had lymph
node metastasis. The patients’ gender, age, tumor size,
macroscopical type, lymph node status and differenti-
ation were obtained from surgical and/or pathological
records at the hospital. The mean age of the patients
was 62 years old. According to the WHO classifica-
tion, tumor differentiation was graded as grade I (high),
grade II (moderate) and grade III (low). All pathologi-
cal slides including normal specimens and tumors were
confirmed by two pathologists (Zhu ZL and Wang ZM).
2.2. Immunohistochemical staining
Immunohistochemical staining was performed on 5-
um thick formalin-fixed paraffin-embedded sections.
The sections were incubated at 60◦ for 12 hours, de-
paraffinized and then rehydrated. The sections were
transferred to 0.01M Tris-EDTA buffer (pH9.0) and
subjected to high pressure cooker for 8 minutes and in-
cubated at room temperature for 30 minutes for antigen
retrieval. The sections were then washed in phosphate
buffered saline (PBS, pH7.4) and incubated with 3%
H2O2 in methanol for 20 minutes, to block endoge-
nous peroxidase activity. Nonspecific binding of anti-
body was prevented by preincubating the sections with
1.5% horse serum (Fuzhou Maixim Biology Technolo-
gy Limited Company, Fuzhou, Fujian Province, China)
in PBS for 10 minutes. After removing the blocking so-
lution, the sections were incubated with a monoclonal
anti-FXYD-3 primary antibody (received kindly from
Drs. H. Hayed and J. Kleeff, University of Heidelberg,
Heidelberg Germany) in 1:2 diluted in PBS (pH7.4)
over night at 4◦ in a moist chamber. Subsequent-
ly, the sections were incubated with biotinlated anti-
rabbit IgG antibody (Fuzhou Maxim Biology Technol-
ogy Limited Company) for 30 minutes, followed by
an incubation of an avidin-biotin-peroxidase complex
(Fuzhou Maxim Biology Technology Limited Compa-
ny) for 30 minutes. The sections were washed with PBS
between each incubation step. The peroxidase reac-
tion was developed using 3.3 diaminobenzidine (DAB)
(Fuzhou Maixim Biology Technology limited Compa-
ny) for 8 minutes. Then, the sections were rinsed with
water and counterstained with Mayer’s haematoxylin
and then washed, dehydrated in ethanol and mounted
with xylene-based mounting medium. The breast can-
cer sections known for positive FXYD-3 were included
as negative or positive controls. For negative controls,
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PBS or/and purified rabbit IgG (Fuzhou Maixim Biol-
ogy Technology limited Company) were used instead
of the primary antibody. In all runs, there was no stain-
ing in the negative controls, and the positive controls
showed clear staining.
The stained sections were microscopically exam-
ined and evaluated independently by two pathologists
(Zhu ZL and Wang ZM) in a blind fashion without any
clinicopathological information. Cytoplasmic staining
was considered as FXYD-3 positive. The intensity of
the staining was graded as negative (no positive cells),
weak (< 20% positive cells), moderate (20–50% posi-
tive cells) and strong positive (> 50% positive cells). In
statistical analysis, we considered negative, weak and
moderate staining as weak group, and strong staining
as positive group. To avoid artificial effects, tissue in
the areas with poor morphology, necrosis and in the
margins of the sections were not considered.
2.3. Statistical analysis
The Chi-square method was used to examine the re-
lationship of the frequencies of FXYD-3 expression in
normal gastric mucosa and cancer, and the relation-
ship between FXYD-3 expression in cancer and clini-
copathological variables. All P-values cited were two-
sided and P-values < 5% were judged as statistically
significant.
3. Results
3.1. FXYD-3 expression in normal mucosa and
primary tumor
We examined FXYD-3 protein expression in normal
gastric mucosa and gastric cancer, and found that the
expression was in the cytoplasm of normal mucosa ep-
ithelial cells and cancer cells, and there was no nu-
clear staining. Among 29 normal specimens, 15 cas-
es was negative (52%), and 14 cases was positive, in-
cluding 6 (21%) cases with weak, 5 (17%) moderate
and 3 (10%) strong staining (Fig. 1A). Among 51 can-
cers, there were 9 (18%) negative, 8 (16%) weak, 8
(16%) moderate and 26 (50%) strong expressed cases,
the staining was mainly in the cytoplasm of the cancer
cells (Fig. 1B).
Taking into account similar clinicopathological fea-
tures and facilitating statistical analysis, the cases with
negative, weak and moderate staining were grouped as
weak group, and the cases with strong staining as strong
group.
As shown in Fig. 2 of FXYD-3 expression in normal
mucosa and cancer, the rate of strong FXYD-3 expres-
sion in cancer was 51% (26/51), which was significant-
ly higher than that in the normal mucosa, 10% (3/29,
X2 = 13.210, p < 0.0001).
We also compared the staining intensity of the inner
tumor cells with the tumor cells at the invasive margin;
there was no difference in the expression intensity.
3.2. FXYD-3 protein expression in relation to
clinicopathological variables
Table 1 shows the relationship between FXYD-3 ex-
pressions in tumors with the clinicopathological vari-
ables. None of the tumors with polypoid/fungating
growth pattern had strong FXYD-3 expression, while
57% (26 of 46) ulcerative/infiltrating tumors did (X 2 =
5.765, p = 0.016). Besides, FXYD-3 expression was
not significantly correlated with patients’ gender (p =
0.811), age (p = 0.903), tumor size (p = 0.691), lymph
node status (p = 0.490) and histological grade (p =
0.492).
4. Discussion
FXYD-3 is able to associate with and modify the
transport proteins of Na, K-ATPase [13], and to act as
chloride channel or a chloride channel regulator [1].
Although FXYD-3 is a member of the FXYD protein
family, it displays some uncommon characteristics that
differ from the other members of the FXYD family.
In addition, Bibert S et al. [14] identified two splice
variants of human FXYD-3 in CaCo-2 cells, namely,
short human FXYD-3 and long human FXYD-3. Their
results showed that short human FXYD-3 had 72% se-
quence identity with mouse FXYD-3, whereas long hu-
man FXYD-3 was identical to short human FXYD-3
but had a 26-amino acid insertion after the transmem-
brane domain. Short and long human FXYD-3 RNAs
and proteins were differentially expressed during dif-
ferentiation of CaCo-2 cells. Long human FXYD-3
was mainly expressed in undifferentiated cells and short
human FXYD-3 in differentiated cells.
Recently, it has been shown that FXYD-3 not on-
ly expresses in some normal tissues (such as the liv-
er, pancreas, intestine, prostate, lung, brain and skin
etc) [2,10], but also in a growing number of tumors and
tumor cell lines. For example, Morrison et al. used RT-
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Fig. 1. The positive FXYD-3 immunohistochemical staining was in the cytoplasm and/or membrane of glands cells ( ) in normal gastric
mucosa (A) and of cancer cells ( ) in gastric adenocarcinoma tissue (B). there was no nuclear and stromal staining.
PCR and RNA blot methods to determine the expres-
sion of FXYD-3, and found that FXYD-3 expressed in
16 breast cancers and also 11 cell lines of breast can-
cer [5]. At the same time, there were studies showing
that FXYD-3 also expresses in Chinese hamster ovary-
K1 (CHO-k1) cells [15] and human colorectal cancer
cells [16], the positive staining was distributed in in-
tracellular membranes, being not only detected around
the nuclear envelop but also partly overlapping with an
endoplasmic reticulum marker. Subcellular fractiona-
tion by density gradient centrifugation supported this
partial overlapping. The spherical structures observed
were not co-localized with markers for lysosomes, en-
dosomes, and Golgibodies, suggesting that FXYD-3
is distributed in a distinct endoplasmic reticulum re-
gion and the nuclear envelope after synthesis on mem-
branebound ribosomes [15,16]. In present study, our
results also show that the positive staining of FXYD-3
is located in the cytoplasm of gastric gland cells and
gastric adenocarcinoma cells, and there was no nuclear
staining.
FXYD-3 protein expression was also analyzed in
normal pancreatic tissue and pancreatic ductal adeno-
carcinoma (PDCA) by Iacobuzio-Donahue et al. [17]
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Table 1
The relationship between FXYD-3 protein expression and clinicopathological
variables in the patients with gastric adenocarcinoma
Variables N FXYD-3 expression X2 P value
Weak (%) Strong (%)
Gender
Male 38 19 (50) 19 (50) 0.057 0.811
Female 13 6 (46) 7 (54)
Age (years)
 62 29 14 (48) 15 (52) 0.015 0.903
> 62 22 11 (50) 11 (50)
Tumor size (cm)
 3 15 8 (53) 7 (47) 0.158 0.691
> 3 36 17 (47) 19 (53)
Macroscopical
Polypoid/fungating 5 5 (100) 0 5.765 0.016
Ulcerative/infiltrating 46 20 (43) 26 (57)
Lymph node status
Non-metastasis 18 10 (56) 8 (44) 0.476 0.490
Metastasis 33 15 (45) 18 (55)
Grade
I 15 6 (40) 9 (60) 2.410 0.492
II 15 10 (67) 5 (33)
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Fig. 2. Frequency of FXYD-3 protein immumohistochemical staining in normal gastric mucosa and gastric adenocarcinoma.
using cDNA microarrays and Kayed et al. [12] using
QRT-PCR and microarray analysis, in situ hybridiza-
tion and immunohistochemistry, their results showed
that the levels of FXYD-3 protein were increased in
PDAC compared to the normal specimens. In addition,
a similar result has been reported by other research
groups [18,19], in which the expression of FXYD-3
was higher in pancreatic ductal adenocarcinoma than
in the chronic pancreatitis tissue. All above results in-
dicated that overexpression of FXYD-3 in pancreatic
cancer might contribute to the proliferative activity of
the cancer. Grzmil et al. [11] examined the expression
of FXYD-3 protein using the cDNA array and RT-PCR
technique in a set of prostate tumors and the matched
normal prostate tissue, and found that the expression of
FXYD-3 protein was highly increased in prostate car-
cinoma in comparison to the matched normal prostate
tissue, moreover, the expression of FXYD-3 was al-
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so higher in prostate carcinoma cell lines than in the
matched normal epithelial cell samples, in addition,
their results also showed that FXYD-3 silencing by siR-
NA promotes a decreased proliferation in prostate can-
cer. Together with, those results suggested that FXYD-
3 played an important role in cellular growth of prostate
carcinoma.
However, there were some contrary results on the
expression of FXYD-3 in prostate cancer. Vaarala et
al. [20] studied the expression of FXYD-3 protein in
the human prostate cancer cell line and in benign pro-
static hyperplasia tissue, and found that FXYD-3 pro-
tein was highly expressed in benign prostatic hyperpla-
sia tissue, but it was down – regulated expression in
prostate cancer cell line, even non-expression.
In the present study, we also found that FXYD-3
strongly expressed in tumors than in normal gastric mu-
soca samples. The results were similar to the major-
ity of all above results such as in breast cancers [5],
Chinese hamster ovary-K1 (CHO-k1) cells [15], hu-
man colorectal cancer cells [16], pancreatic cancer [12,
17–19] and prostate cancer [11], indicating that the ex-
pression of FXYD-3 was higher in cancer tissue than it
in the corresponding normal tissue, and suggesting that
FXYD-3 protein may be related to tumorgenesis.
To study the fine role of FXYD-3 in tumorogenesis,
Bibert S et al. [21] used human colon adenocarcinoma
cells (Caco-2) to investigate the effect of FXYD-3 si-
lencing on cell proliferation, differentiation and apop-
tosis, and Na, K-ATPase activity and expression. Their
results showed that FXYD-3 silencing had no effect on
cell proliferation. This result is compatible with the
result reported by Grzmil et al. [11]. In addition, Bibert
S et al. [21] also showed that FXYD-3 silencing could
promote cell apoptosis and prevent cell differentiation
of Caco-2 cells. From those results, they supposed
that the most possibility was that FXYD-3 silencing
prevented a proper regulation of Na, K-ATPase, which
led to perturbation of cellular Na+ and K+ homeosta-
sis and changes in the expression of Na, K-ATPase
isozymes, whose functional properties were incompat-
ible with Caco-2 cell differentiation. Overall, further
studies are needed to definitively establish the mecha-
nism of FXYD-3 in tumorogenesis.
In addition, the gross appearance of tumors is af-
fected by many factors such as benign, malignant,
location, growth rate, invasive ability, necrosis and
hemorrhage etc. Therefore, to a certain extent, the
gross type of tumor can reflect the invasive ability
of tumor. In general, the invasive ability of gas-
tric cancer in ulcerative/infiltrating pattern is stronger
than it in polypoid/fungating pattern. In the present
study, we also found that none of the five tumors with
polypoid/fungating growth pattern had strong expres-
sion for FXYD-3, while 26 of 46 tumors with ulcer-
ative/infiltrating pattern showed strong expression of
FXYD-3. The result suggested that overexpression of
FXYD-3 in gastric adenocarcinoma might be related
to the invasive ability of cancer. Gorden et al. [22]
studied the expression of FXYD-3 protein in the ade-
nocarcinoma of the lung and found that FXYD-3 ex-
pression was positively related to poorer survival of the
patients. Unfortunately, we did not have survival data
for the patients in the present study, we could not see
if the FXYD-3 was further related to patient survival.
However, our result showed that FXYD-3 expression
may be involved in invasion of gastric cancer.
5. Conclusion
Up-regulated expression of FXYD-3 protein may be
involved in tumourgenesis and invasion of gastric ade-
nocarcinoma.
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